Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Target Engagement of Nebulised GSK3008348 in IPF
NCT03069989Phase 1Terminated
- Sponsor
- GSK
- Start
- Jun 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GSK3008348 with Placebo (2 arms). Primary endpoints: Volume of Distribution (VT) of [18F]-FBA-A20FMDV2 in the Whole Lung, Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 62 days and 6 more. Started Jun 2017; status: terminated.
02
Drugs
GSK3008348
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03069989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069989.